Market Summary
USD1.61-0.09
Market Closed-5.29%
CDXS Alerts
CDXS Stock Price
CDXS RSI Chart
CDXS Valuation
CDXS Price/Sales (Trailing)
CDXS Profitability
CDXS Fundamentals
CDXS Revenue
CDXS Earnings
Price Action
52 Week Range
1.586.98
(Low)(High)
Last 7 days
-19.4%
Last 30 days
-1.7%
Last 90 days
-38.2%
Trailing 12 Months
-74.9%
CDXS Financial Health
CDXS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for CDXS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-11 | Norrett Kevin | bought | 15,479 | 1.7199 | 9,000 | chief operating officer |
2023-09-08 | Ryali Sriram | bought | 19,856 | 1.7044 | 11,650 | chief financial officer |
2023-09-08 | DILLY STEPHEN GEORGE | bought | 100,952 | 1.7263 | 58,479 | see remarks |
2023-09-08 | Fitzgerald Margaret Nell | bought | 20,064 | 1.6955 | 11,834 | see remarks |
2023-06-13 | Singhvi Rahul | acquired | - | - | 34,602 | - |
2023-06-13 | Aaker Jennifer | acquired | - | - | 34,602 | - |
2023-06-13 | PARKER H STEWART | acquired | - | - | 34,602 | - |
2023-06-13 | WOLF DENNIS P | acquired | - | - | 34,602 | - |
2023-06-13 | Smith David V | acquired | - | - | 34,602 | - |
2023-06-13 | Dorgan Byron L | acquired | - | - | 34,602 | - |
Which funds bought or sold CDXS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -4.22 | -1,278 | 2,352 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -70.27 | -246,730 | 62,110 | -% |
2023-08-18 | Legato Capital Management LLC | sold off | -100 | -468,872 | - | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 8.26 | -1,845,160 | 5,044,840 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 34.49 | -30,634 | 308,308 | -% |
2023-08-15 | Miller Investment Management, LP | unchanged | - | -15,669 | 32,740 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 1,005 | 406,343 | 469,109 | -% |
2023-08-15 | CAPTRUST FINANCIAL ADVISORS | new | - | 29,352 | 29,352 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 3.7 | -361,567 | 849,047 | -% |
2023-08-15 | CAXTON ASSOCIATES LP | unchanged | - | -39,022 | 81,539 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
CDXS Alerts
Schedule 13G FIlings of Codexis
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Aug 08, 2023 | blackrock inc. | 10.4% | 6,932,344 | SC 13G/A | |
| Feb 14, 2023 | nantahala capital management, llc | 6.8% | 4,487,782 | SC 13G/A | |
| Feb 14, 2023 | casdin capital, llc | 0% | 0 | SC 13G/A | |
| Feb 10, 2023 | ark investment management llc | 6.00% | 3,941,985 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 5.54% | 3,642,208 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 9.4% | 6,154,933 | SC 13G/A | |
| Jan 18, 2023 | baillie gifford & co | 9.46% | 6,210,551 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 5.24% | 3,400,490 | SC 13G | |
| Feb 09, 2022 | ark investment management llc | 5.00% | 3,244,040 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 7.9% | 5,144,949 | SC 13G/A |
Recent SEC filings of Codexis
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 07, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | SC 13G/A | Major Ownership Report | |
| Aug 03, 2023 | S-8 | Employee Benefits Plan | |
| Aug 03, 2023 | 10-Q | Quarterly Report | |
| Aug 03, 2023 | 8-K | Current Report | |
| Aug 03, 2023 | S-8 | Employee Benefits Plan |
Peers (Alternatives to Codexis)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 32.2B | 7.0B | -5.38% | -12.23% | 28.38 | 4.6 | 5.03% | -14.68% |
MTD | 23.9B | 4.0B | -3.30% | -3.12% | 26.91 | 6.05 | 2.30% | 16.37% |
ILMN | 21.1B | 4.5B | -17.36% | -28.94% | -5.03 | 4.72 | -4.92% | -21931.58% |
TECH | 11.0B | 1.1B | -9.93% | -5.35% | 38.64 | 9.7 | 2.81% | 4.86% |
| MID-CAP | ||||||||
RGEN | 9.4B | 134.2M | 4.73% | -21.54% | 68.08 | 70.03 | -82.77% | -13.43% |
| SMALL-CAP | ||||||||
PACB | 2.3B | 146.1M | -8.89% | 61.75% | -7.06 | 15.43 | 4.72% | -55.19% |
QTRX | 960.9M | 112.0M | 5.18% | 169.83% | -14.6 | 8.58 | 0.83% | 16.42% |
ADPT | 749.3M | 189.6M | -19.57% | -31.57% | -3.92 | 3.95 | 18.74% | 17.75% |
HBIO | 175.9M | 114.1M | -1.44% | 44.37% | -32.4 | 1.54 | -5.49% | -48.58% |
CDXS | 112.4M | 99.2M | -1.73% | -74.89% | -1.98 | 1.13 | -26.56% | -199.52% |
CDXC | 104.0M | 80.9M | -10.97% | -2.13% | -16.02 | 1.29 | 17.20% | 77.07% |
BNGO | 99.1M | 31.5M | -1.32% | 40.85% | -0.68 | 3.14 | 35.12% | -38.47% |
CSBR | 71.9M | 52.7M | -20.39% | -41.08% | -9.51 | 1.36 | 2.10% | -1984.29% |
NSTG | 68.4M | 143.9M | -41.73% | -89.43% | -0.41 | 0.48 | 0.71% | -18.99% |
Codexis News
Returns for CDXS
Cumulative Returns on CDXS
-0.3%
10-Year Cumulative Returns
-12.1%
7-Year Cumulative Returns
-37.6%
5-Year Cumulative Returns
-48.1%
3-Year Cumulative Returns
Risks for CDXS
What is the probability of a big loss on CDXS?
99.6%
Probability that Codexis stock will be more than 20% underwater in next one year
79.2%
Probability that Codexis stock will be more than 30% underwater in next one year.
63.9%
Probability that Codexis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CDXS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Codexis was unfortunately bought at previous high price.
Drawdowns
Financials for Codexis
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -14.7% | 99,150,000 | 116,233,000 | 138,590,000 | 132,717,000 | 135,016,000 | 122,063,000 | 104,754,000 | 101,287,000 | 82,903,000 | 72,417,000 | 69,056,000 | 66,672,000 | 70,193,000 | 67,545,000 | 68,458,000 | 65,876,000 | 60,916,000 | 62,135,000 | 60,594,000 | 66,249,000 | 59,287,000 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 78,123,000 | 75,528,000 | 73,962,000 | 71,889,000 | 76,020,000 | 76,988,000 |
| S&GA Expenses | 5.2% | 54,576,000 | 51,867,000 | 52,172,000 | 51,583,000 | 51,491,000 | 53,630,000 | 49,323,000 | 46,342,000 | 41,732,000 | 37,459,000 | 35,049,000 | 33,630,000 | 32,702,000 | 32,076,000 | 31,502,000 | 30,986,000 | 30,461,000 | 29,960,000 | 29,291,000 | 30,352,000 | 30,997,000 |
| R&D Expenses | -2.3% | 75,499,000 | 77,254,000 | 80,099,000 | 76,767,000 | 70,111,000 | 63,848,000 | 55,919,000 | 49,917,000 | 46,762,000 | 44,789,000 | 44,185,000 | 42,703,000 | 39,404,000 | 36,825,000 | 33,873,000 | 32,515,000 | 31,721,000 | 30,817,000 | 29,978,000 | 31,882,000 | 32,020,000 |
| EBITDA | 100.0% | - | -41,881,000 | -27,880,000 | -26,024,000 | -14,330,000 | -16,687,000 | -17,963,000 | -12,148,000 | -20,834,000 | -24,047,000 | -22,627,000 | -19,349,000 | -12,942,000 | -13,409,000 | -10,877,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.36 | -0.20 | -0.20 | -0.11 | -0.14 | -0.17 | -0.12 | -0.25 | -0.33 | -0.33 | -0.29 | -0.18 | -0.20 | -0.16 | - | - | - | - | - | - |
| Interest Expenses | -11.1% | 32,000 | 36,000 | 34,000 | 30,000 | 23,000 | 16,000 | 14,000 | 43,000 | 51,000 | 51,000 | 52,000 | 48,000 | 44,000 | 31,000 | 49,000 | 39,000 | 51,000 | 84,000 | 84,000 | 71,000 | 69,333 |
| Earnings Before Taxes | -18.9% | -56,552,000 | -47,570,000 | -33,316,000 | -30,985,000 | -18,647,000 | -20,372,000 | -21,090,000 | -14,881,000 | -23,310,000 | -25,090,000 | -23,671,000 | -20,389,000 | -13,978,000 | -14,432,000 | -11,918,000 | -11,775,000 | -14,098,000 | -11,353,000 | -10,915,000 | -9,510,000 | -17,599,000 |
| EBT Margin | 100.0% | - | -0.41 | -0.24 | -0.23 | -0.14 | -0.17 | -0.20 | -0.15 | -0.28 | -0.35 | -0.34 | -0.31 | -0.20 | -0.21 | -0.17 | - | - | - | - | - | - |
| Net Income | -18.6% | -56,736,000 | -47,853,000 | -33,592,000 | -31,178,000 | -18,942,000 | -20,567,000 | -21,279,000 | -15,009,000 | -23,347,000 | -25,426,000 | -24,010,000 | -20,725,000 | -14,288,000 | -14,451,000 | -11,935,000 | -11,761,000 | -14,092,000 | -11,320,000 | -10,878,000 | -9,447,000 | -17,685,000 |
| Net Income Margin | 100.0% | - | -0.41 | -0.24 | -0.23 | -0.14 | -0.17 | -0.20 | -0.15 | -0.28 | -0.35 | -0.35 | -0.31 | -0.20 | -0.21 | -0.17 | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 7,501,000 | 2,977,000 | -6,793,000 | -29,413,000 | -35,380,000 | -28,095,000 | -26,255,000 | -26,303,000 | -27,016,000 | -20,212,000 | -21,308,000 | -20,111,000 | -15,180,000 | -16,290,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -5.2% | 207 | 218 | 250 | 235 | 235 | 235 | 246 | 228 | 212 | 212 | 222 | 138 | 142 | 149 | 149 | 146 | 147 | 101 | 79.00 | 79.00 | 76.00 |
| Current Assets | -7.6% | 120 | 130 | 163 | 146 | 145 | 145 | 162 | 174 | 172 | 174 | 184 | 103 | 106 | 115 | 114 | 110 | 110 | 64.00 | 68.00 | 68.00 | 66.00 |
| Cash Equivalents | -10.4% | 92.00 | 103 | 114 | 109 | 90.00 | 94.00 | 119 | 119 | 130 | 140 | 149 | 72.00 | 76.00 | 87.00 | 92.00 | 92.00 | 93.00 | 47.00 | 54.00 | 54.00 | 54.00 |
| Inventory | 2.8% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Net PPE | -1.2% | 23.00 | 24.00 | 23.00 | 23.00 | 24.00 | 23.00 | 21.00 | 16.00 | 11.00 | 10.00 | 10.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 |
| Goodwill | 0% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Liabilities | -10.2% | 83.00 | 92.00 | 106 | 81.00 | 76.00 | 77.00 | 82.00 | 58.00 | 50.00 | 48.00 | 52.00 | 47.00 | 47.00 | 50.00 | 44.00 | 44.00 | 48.00 | 50.00 | 23.00 | 24.00 | 23.00 |
| Current Liabilities | -6.7% | 36.00 | 38.00 | 49.00 | 32.00 | 30.00 | 29.00 | 33.00 | 33.00 | 24.00 | 23.00 | 25.00 | 20.00 | 19.00 | 22.00 | 15.00 | 15.00 | 17.00 | 19.00 | 18.00 | 18.00 | 16.00 |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 |
| Shareholder's Equity | -1.5% | 124 | 126 | 145 | 154 | 159 | 159 | 164 | 169 | 163 | 164 | 170 | 91.00 | 95.00 | 99.00 | 106 | 103 | 99.00 | 51.00 | 56.00 | 55.00 | 53.00 |
| Retained Earnings | -2.6% | -455 | -443 | -421 | -408 | -398 | -396 | -387 | -377 | -379 | -375 | -366 | -362 | -356 | -350 | -342 | -341 | -342 | -335 | -330 | -330 | -328 |
| Additional Paid-In Capital | 1.7% | 580 | 570 | 566 | 563 | 558 | 555 | 552 | 547 | 543 | 539 | 537 | 453 | 451 | 449 | 448 | 444 | 441 | 387 | 387 | 385 | 381 |
| Shares Outstanding | 4.7% | 70.00 | 67.00 | 66.00 | 66.00 | 65.00 | 65.00 | 65.00 | 65.00 | 64.00 | 64.00 | 64.00 | 59.00 | 59.00 | 59.00 | 59.00 | 58.00 | 55.00 | 54.00 | 52.00 | 54.00 | 53.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -104.9% | -648 | 13,258 | 11,284 | 7,027 | -12,899 | -19,013 | -14,267 | -16,419 | -19,701 | -21,479 | -16,464 | -18,633 | -16,149 | -11,134 | -12,560 | -9,619 | -9,862 | -12,760 | -14,094 | -5,748 | -9,365 |
| Share Based Compensation | -3.8% | 12,987 | 13,502 | 14,531 | 14,646 | 13,131 | 12,744 | 11,593 | 10,183 | 9,151 | 8,246 | 7,728 | 7,252 | 7,000 | 7,049 | 6,943 | 7,465 | 7,503 | 7,972 | 7,889 | 8,086 | 8,149 |
| Cashflow From Investing | 9.6% | -6,131 | -6,780 | -13,578 | -19,091 | -28,779 | -28,971 | -21,422 | -18,430 | -8,203 | -7,520 | -5,748 | -3,674 | -4,898 | -3,981 | -3,665 | -3,944 | -2,551 | -3,195 | -2,766 | -2,318 | -1,778 |
| Cashflow From Financing | 325.2% | 8,747 | 2,057 | -575 | 1,512 | 2,247 | 2,470 | 3,767 | 82,927 | 82,184 | 81,844 | 80,808 | 1,644 | 3,207 | 55,024 | 53,961 | 51,790 | 52,502 | 39,251 | 38,569 | 38,351 | 35,831 |
CDXS Income Statement
2023-06-30Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 21,323 | $ 38,406 | $ 34,305 | $ 73,746 |
| Costs and operating expenses: | ||||
| Cost of product revenue | 3,178 | 11,270 | 7,698 | 19,791 |
| Research and development | 17,334 | 19,089 | 33,988 | 38,590 |
| Selling, general and administrative | 13,365 | 10,656 | 28,765 | 26,360 |
| Restructuring charges | 72 | 0 | 145 | 0 |
| Total costs and operating expenses | 33,949 | 41,015 | 70,596 | 84,741 |
| Loss from operations | (12,626) | (2,609) | (36,291) | (10,995) |
| Interest income | 1,121 | 140 | 2,209 | 182 |
| Other expense, net | (9) | (63) | (33) | (66) |
| Loss before income taxes | (11,514) | (2,532) | (34,115) | (10,879) |
| Provision for income taxes | 9 | 108 | 25 | 117 |
| Net loss | $ (11,523) | $ (2,640) | $ (34,140) | $ (10,996) |
| Net loss per share, basic (in dollars per share) | $ (0.17) | $ (0.04) | $ (0.51) | $ (0.17) |
| Net loss per share, diluted (in dollars per share) | $ (0.17) | $ (0.04) | $ (0.51) | $ (0.17) |
| Weighted average common stock shares used in computing net loss per share, basic (in shares) | 67,573 | 65,288 | 66,756 | 65,193 |
| Weighted average common stock shares used in computing net loss per share, diluted (in shares) | 67,573 | 65,288 | 66,756 | 65,193 |
| Product revenue | ||||
| Revenues: | ||||
| Total revenues | $ 11,048 | $ 34,645 | $ 19,412 | $ 65,335 |
| Research and development revenue | ||||
| Revenues: | ||||
| Total revenues | $ 10,275 | $ 3,761 | $ 14,893 | $ 8,411 |
CDXS Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 92,093 | $ 113,984 |
| Restricted cash, current | 524 | 521 |
| Financial assets: | ||
| Accounts receivable | 8,806 | 31,904 |
| Contract assets | 2,248 | 2,116 |
| Unbilled receivables | 10,691 | 7,016 |
| Total financial assets | 21,745 | 41,036 |
| Less: allowances | (133) | (163) |
| Total financial assets, net | 21,612 | 40,873 |
| Inventories | 2,052 | 2,029 |
| Prepaid expenses and other current assets | 3,763 | 5,487 |
| Total current assets | 120,044 | 162,894 |
| Restricted cash | 1,530 | 1,521 |
| Investment in non-marketable equity securities ($0 and $13,921 with a related party) | 21,378 | 20,510 |
| Right-of-use assets - Operating leases, net | 36,745 | 39,263 |
| Property and equipment, net | 23,325 | 22,614 |
| Goodwill | 3,241 | 3,241 |
| Other non-current assets | 498 | 350 |
| Total assets | 206,761 | 250,393 |
| Current liabilities: | ||
| Accounts payable | 4,042 | 3,246 |
| Accrued compensation | 8,538 | 11,453 |
| Other accrued liabilities | 7,001 | 15,279 |
| Current portion of lease obligations - Operating leases | 5,626 | 5,360 |
| Deferred revenue | 10,529 | 13,728 |
| Total current liabilities | 35,736 | 49,066 |
| Deferred revenue, net of current portion | 10,110 | 16,881 |
| Long-term lease obligations - Operating leases | 35,379 | 38,278 |
| Other long-term liabilities | 1,405 | 1,371 |
| Total liabilities | 82,630 | 105,596 |
| Commitments and Contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding | 0 | 0 |
| Common stock, $0.0001 par value per share; 100,000 shares authorized; 69,804 shares and 65,811 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 6 | 6 |
| Additional paid-in capital | 579,555 | 566,081 |
| Accumulated deficit | (455,430) | (421,290) |
| Total stockholders' equity | 124,131 | 144,797 |
| Total liabilities and stockholders' equity | $ 206,761 | $ 250,393 |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.